Purpose of Review <p>This review aims to provide a comprehensive overview of recent advancements in stem cell research, with a particular focus on hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). It seeks to address how emerging technologies are enhancing clinical translation and to evaluate the current challenges limiting the widespread application of stem cell–based therapies.</p> Recent Findings <p>Recent technological innovations, including biomimetic three-dimensional culture systems, automated GMP-compliant bioreactors, and scalable manufacturing platforms, have significantly improved ex vivo stem cell expansion and therapeutic applicability. In addition, iPSC-derived, HLA-engineered hematopoietic and immune cells have emerged as promising universal, off-the-shelf therapeutic alternatives, overcoming limitations related to donor availability and immune compatibility. Advances in molecular and genomic engineering, such as CRISPR/Cas9 genome editing, single-cell multi-omics technologies, and nanotechnology-based delivery systems, have further enhanced precision, efficiency, and functional outcomes in stem cell applications.</p> Summary <p> Stem cell–based therapies, particularly those involving HSCs, remain a cornerstone in the treatment of hematological, immunological, and genetic disorders. Meanwhile, MSCs play a crucial role in immunomodulation and tissue repair. Despite these advances, significant challenges persist, including issues related to genetic stability, immunogenicity, ethical and regulatory constraints, and economic feasibility. Addressing these limitations will be essential for achieving safe, scalable, and globally accessible stem cell therapies, ultimately shaping the future of regenerative medicine and clinical translation.</p>